RetiSpec partners with Gentex to commercialize Alzheimer's disease detection technology

RetiSpec_logo.jpg

RetiSpec Inc. announced today that it is partnering with Gentex Corporation to engineer, manufacture and commercialize technology for the early detection of Alzheimer's disease. By harnessing hyperspectral imagery, RetiSpec's patented technology allows for the rapid, simple and cost-effective identification of Alzheimer's biomarkers years before the emergence of clinical symptoms.

Previous
Previous

OBIO job fair November 2020

Next
Next

VoxNeuro signs agreement with UHN to launch concussion study